Search | Clinical Trials Finder

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Mosunetuzumab, ClonoSEQ; Drug · Device
Lead sponsor: Danielle Wallace; Other
Eligibility: 70 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza Vaccination
Interventions: Influenza vaccination; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Interventions: Piflufolastat, PSMA PET/CT Scan, PSMA PET/MRI scan, Biospecimen Collection, Electronic Health Record Review; Drug · Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Postoperative Pain
Interventions: TENS Unit; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Alcohol Misuse, Homeless
Interventions: Smart-T Alcohol, Usual Care; Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
Interventions: ADXS-503, Pembrolizumab; Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more

Conditions: HIV
Interventions: Siempre Seguiré; Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older · Male only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions: PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost; Diagnostic Test · Drug · Radiation
Lead sponsor: Martin T. King, MD, PhD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts

Conditions: NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions: This is a non-interventional, observational, prospective study.; Other
Lead sponsor: Bladder Cancer Advocacy Network; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Wilms Tumor, Sarcoma, Spindle Cell, Sarcoma Rhabdoid, Childhood Sarcoma of Soft Tissue
Interventions: Not listed
Lead sponsor: Florida International University; Other
Eligibility: Up to 21 Years
Enrollment: 14 participants
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Arrhythmias, Cardiac
Interventions: Electromechanical wave imaging (EWI); Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Suicide, Suicide Attempt
Interventions: Pathfinding, Treatment As Usual (TAU); Behavioral
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes or With New Hyperglycemia
Interventions: Glucommander, Standard insulin infusion algorithm; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 4
States / cities: Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington

Conditions: Uterine Cervical Neoplasms, Ovarian Neoplasms, Gynecologic Neoplasms, Fallopian Tube Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Peritoneal Neoplasms
Interventions: Specialized Symptom Management and Supportive Care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: additional educational material, Standard of care; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Conditions: Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
Interventions: AK002, Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Gilbert, Arizona • Chula Vista, California + 35 more

Conditions: Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Niraparib, Quality-of-Life Assessment, Questionnaire Administration, Temozolomide; Biological · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer, Ductal Adrenocarcinoma, Exocrine Pancreatic Cancer
Interventions: PCI-27483, Gemcitabine; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • Anaheim, California • Titusville, Florida + 13 more

Conditions: Stroke, Stroke, Acute, Balance; Distorted, Balance; Impairment, Gait, Unsteady
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Wallingford, Connecticut • Washington D.C., District of Columbia • Sandwich, Massachusetts + 1 more

Conditions: Carcinoma, Non Small Cell Lung (NSCLC)
Interventions: Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hemorrhagic Shock
Interventions: Glutamine, Ringer's Lactate, Placebo (for Glutamine); Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 21 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
Interventions: Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy; Drug · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ulcerative Colitis
Interventions: Tacrolimus, Vedolizumab, Placebo; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

Study of Immune Responses to Influenza Vaccination

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy

Evaluating Transcutaneous Electrical Nerve Stimulation for Postoperative Pain After Video-Assisted Thoracotomy Surgery

Efficacy of a Smartphone-Based JITAI to Reduce Drinking Among Adults Experiencing Homelessness

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)

Drug Sensitivity and Mutation Profiling

Ablation Guided Via Precision Imaging Using Electromechanical Wave Imaging

Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy

Continous Positive Airway Pressure (CPAP) Compliance Study

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

A Multisite Exploration of Balance Perturbations With and Without Body Weight Support

Locally Advanced NSCLC Hyperfractionated RT

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC